Minocycline HCl |
| Catalog No.GC11861 |
Minocycline HCl은 구강 내 복용이 가능하고 혈뇨 장벽을 통과할 수 있는 반합성 테트라사이클린 항생제이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 13614-98-7
Sample solution is provided at 25 µL, 10mM.
Minocycline HCl은 구강 내 복용이 가능하고 혈뇨 장벽을 통과할 수 있는 반합성 테트라사이클린 항생제이다. Minocycline HCl은 낮은 산소 유도 인자 (HIF-1α) 억제제로 항암, 항염증 및 글루타마테 반작용 효과 그리고 신경 보호 및 항우울 성질을 가지고 있다[2]. Minocycline HCl은 박테리아 리보솜 30S 서브 유닛과 결합하여 박테리아 단백질 합성을 억제함으로써 항균 효과를 발휘한다[3].
체외 실험에서 Minocycline HCl（10μM）를 SH-SY5Y 세포에 24시간 동안 처리하여 6-히드록시도파민（6-OHDA）에 의한 세포 사망을 현저하게 억제하고 세포 DNA 조각화와 염색질 응축을 억제했다[4]. Minocycline HCl（0-100μM）를 유방암 세포 라인（OVCAR-3, SKOV-3, A2780 세포）에 24-72시간 동안 처리하여 세포 증식과 균락 형성을 억제하고 세포라인 단백질 A, B, E의 표현을 하강시키고 DNA 합성을 억제하고 DNA 사다리, 시스테인-3 활성화 및 PARP-1 절단을 유도했다[5].
체내 실험에서 복강 주사로 Minocycline HCl（25, 50mg/kg）를 척수손상 모델 쥐에 28일 동안 치료하고 축엽의 무결성을 현저하게 보호하고 조직 손실을 예방하고 운동 행동을 개선했다[6]. Minocycline HCl（3, 10mg/kg）를 일시성 중뇌동맥 차단（TMCAO）모델인 쥐의 목정맥에 주입하고 뇌경색 면적을 효과적으로 줄이고 신경 기능 결함을 현저하게 개선했다[7].
References:
[1] Zhou J, Yang J, Dai M, et al. A combination of inhibiting microglia activity and remodeling gut microenvironment suppresses the development and progression of experimental autoimmune uveitis[J]. Biochemical Pharmacology, 2020, 180: 114108.
[2] Pajarillo E, Nyarko-Danquah I, Digman A, et al. Mechanisms of manganese-induced neurotoxicity and the pursuit of neurotherapeutic strategies[J]. Frontiers in Pharmacology, 2022, 13: 1011947.
[3] Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics[J]. Current Molecular Pharmacology, 2021, 14(6): 1046-1065.
[4] Ossola B, Lantto T A, Puttonen K A, et al. Minocycline protects SH‐SY5Y cells from 6‐hydroxydopamine by inhibiting both caspase‐dependent and‐independent programmed cell death[J]. Journal of neuroscience research, 2012, 90(3): 682-690.
[5] Pourgholami M H, Mekkawy A H, Badar S, et al. Minocycline inhibits growth of epithelial ovarian cancer[J]. Gynecologic oncology, 2012, 125(2): 433-440.
[6] Wells J E A, Hurlbert R J, Fehlings M G, et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice[J]. Brain, 2003, 126(7): 1628-1637.
[7] Xu L, Fagan S C, Waller J L, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats[J]. BMC neurology, 2004, 4: 1-7.
| 세포 실험 [1]: | |
세포 라인 | SH-SY5Y 세포 |
제조 방법 | SH-SY5Y 세포는 신경 독소에 24시간과 48시간 동안 노출하기 전에 다양한 농도의 Minocycline HCl（1, 10, 50μM）로 24시간 동안 사전 재배되었습니다. |
반응 조건 | 1, 10, 50μM; 24시간 동안 |
응용 분야 | Minocycline HCl은 6-히드록시도파민(6-OHDA)에 의한 세포 사망을 현저하게 방지했고 약물 농도가 10μM일 때 현저한 보호 효과를 관찰했습니다. |
| 동물 실험 [2]: | |
동물 모형 | 수컷 CD‐1 쥐 |
제조 방법 | 쥐에게는 복강 주사로 식염수 또는 50mg/kg Minocycline HCl을 투여했습니다. 그 후 24시간 후에 50mg/kg의 두 번째 주사를 받았습니다. 치료받은 쥐는 다음 5일 동안 매일 25mg/kg의 용량을 주사 받았습니다. 모든 동물은 척수손상（SCI） 후 28일째에 사망되었습니다. |
제형 | 25、50mg/kg; i.p. |
응용 분야 | SCI 모델의 쥐에서 Minocycline HCl은 축엽의 무결성을 현저하게 보호하고 조직 손실을 예방하고 운동 행동 개선을 이끌어냈습니다. |
References: | |
| Cas No. | 13614-98-7 | SDF | |
| Chemical Name | (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;hydrochloride | ||
| Canonical SMILES | CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl | ||
| Formula | C23H28ClN3O7 | M.Wt | 493.94 |
| Solubility | ≥ 60.7 mg/mL in DMSO with gentle warming, ≥ 7.86 mg/mL in Water with gentle warming | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0245 mL | 10.1227 mL | 20.2454 mL |
| 5 mM | 404.9 μL | 2.0245 mL | 4.0491 mL |
| 10 mM | 202.5 μL | 1.0123 mL | 2.0245 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Aucubin inhibit the inflammatory responses in microglia. BV2 cells were treated with Aucubin (25, 50, 100 µM) or minocycline (MINO; 50µM) for 12 h and were stimulated with 1 µg/mL LPS for another 24 h. (A, B, C) iNOS and COX-2 protein level were detected and quantified in microglia.
We also diluted tert-butyl hydroperoxide and minocycline (MINO; GLPBIO) in saline to stock concentrations of 100mM and 50 mM, respectively.
Int Immunopharmacol 111 (2022): 109163. PMID: 35994851 IF: 5.5999 -
Related Biological Data
Impairment of synaptic plasticity in hippocampus caused by chronic alcohol exposure were alleviated by administration of minocycline.(b) Confocal z stack and three-dimensional (3D) surface rendering showing the presence of PSD95 in microglia. Scale bar, 5 μm and 1 μm.
According to previous studies, the dose of minocycline (GLPBIO, Cat.NO. GC11861) was 30 mg/kg/day.Single daily injections of Mino (i.p.) were started 3 days prior to alcoholexposure and continued for 28 days.
Experimental Neurology (2022): 114061. PMID: 35367455 IF: 5.33 -
Related Biological Data
The NO inhibitory activity of clerodane diterpenoids from Tinospora sagittata. BV-2 cells were treated with each clerodane diterpenoid and the positive control Mino (with various concentrations) in the presence of 200 ng/mL LPS for 24 h, the supernatants were collected for measurement of NO production.
After incubation for 24 h, the normal control and LPS groups were treated with fresh medium, while the other groups were treated with compounds 2 and 12 and Mino (15 μM)(GLPBIO).
Phytochemistry, 2024, 218: 113932. PMID: 38056516 IF: 3.8001
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *